Mixed Dyslipidemia - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Mixed Dyslipidemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H2 2014', provides an overview of the Mixed Dyslipidemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mixed Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mixed Dyslipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mixed Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mixed Dyslipidemia Overview 6
Therapeutics Development 7
Pipeline Products for Mixed Dyslipidemia - Overview 7
Pipeline Products for Mixed Dyslipidemia - Comparative Analysis 8
Mixed Dyslipidemia - Therapeutics under Development by Companies 9
Mixed Dyslipidemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Mixed Dyslipidemia - Products under Development by Companies 13
Mixed Dyslipidemia - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
CymaBay Therapeutics, Inc. 15
Intas Pharmaceuticals Ltd. 16
Novartis AG 17
Pfizer Inc. 18
Mixed Dyslipidemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
bococizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
evolocumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
INSUPR-001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MAT-9001 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MBX-8025 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TAP-311 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Mixed Dyslipidemia - Recent Pipeline Updates 36
Mixed Dyslipidemia - Dormant Projects 45
Mixed Dyslipidemia - Discontinued Products 46
Mixed Dyslipidemia - Product Development Milestones 47
Featured News & Press Releases 47
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 47
Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol 50
Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products under Development for Mixed Dyslipidemia, H2 2014 7
Number of Products under Development for Mixed Dyslipidemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Mixed Dyslipidemia - Pipeline by Amgen Inc., H2 2014 14
Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2014 15
Mixed Dyslipidemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 16
Mixed Dyslipidemia - Pipeline by Novartis AG, H2 2014 17
Mixed Dyslipidemia - Pipeline by Pfizer Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H2 2014 36
Mixed Dyslipidemia - Dormant Projects, H2 2014 45
Mixed Dyslipidemia - Discontinued Products, H2 2014 46